Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

DeAngelo, D. J., Pullarkat, V. A., Piris-Villaespesa, M., George, T. I., Patel, J. L., Ustun, C., Bose, P., Heaney, M. L., Sachs, J., Sun, L., Pilla, A., Exter, B., Jolin, H. A., & Tashi, T. (2022). Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM). Blood, 140(Supplement 1), 1512–1513. https://doi.org/10.1182/blood-2022-156311

Authors:

Daniel J. DeAngelo

Vinod Pullarkat

Miguel Piris‐Villaespesa

Tracy I. George

Jay Patel

Celalettin Üstün

Prithviraj Bose

Mark L. Heaney

Jessica Sachs

Lei Sun

Amanda Pilla